This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morse, M. A. Articles by Chung, F.-L. Search for Related Content PubMed PubMed Citation Articles by Morse, M. A. Articles by Chung, F.-L.

Structure-Activity Relationships for Inhibition of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone Lung Tumorigenesis by Arylalkyl Isothiocyanates in A/J Mice¹

Division of Chemical Carcinogenesis, Naylor Dana Institute for Disease Prevention, American Health Foundation, Valhalla, New York 10595

Phenethyl isothiocyanate (PEITC), 3-phenylpropyl isothiocyanate (PPITC), 4-phenylbutyl isothiocyanate (PBITC), and the newly synthesized 5-phenylpentyl isothiocyanate (PPeITC), 6-phenylhexyl isothiocyanate (PHITC), and 4-(3-pyridyl)butyl isothiocyanate (PyBITC) were tested for their abilities to inhibit tumorigenicity and DNA methylation induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in the lungs of A/J mice. Mice were administered isothiocyanates by gavage for 4 consecutive days at doses of 5, 1, or 0.2 µmol/day prior to administration of 10 µmol of NNK by i.p. injection. Mice were sacrificed 16 weeks after NNK administration and pulmonary adenomas were quantitated. PEITC effectively inhibited NNK-induced lung tumors at a dose of 5 µmol/day but was not inhibitory at doses of 1 or 0.2 µmol/day. PPITC, PBITC, PPeITC, and PHITC were all considerably more potent inhibitors of NNK lung tumorigenesis than PEITC. While virtually no differences in inhibitory activity could be ascertained for PPITC, PBITC, and PPeITC, PHITC appeared to be the most potent tumor inhibitor of all of the compounds. At a dose of 0.2 µmol/day, PHITC pretreatment reduced tumor multiplicity by 85%. PyBITC, an analogue of both NNK and PBITC, was ineffective as an inhibitor. Using the same protocol, the compounds were found to have qualitatively similar inhibitory effects on NNK-induced DNA methylation when administered at 1 µmol/day. These results extend our previous findings that increased alkyl chain length enhances the inhibitory activity of an arylalkyl isothiocyanate toward NNK lung tumorigenesis and demonstrate the exceptional chemopreventive potentials of two new isothiocyanates, PPeITC and PHITC.

¹ This is paper 11 in the series "Dietary Inhibitors of Chemical Carcinogenesis." This work was supported by National Cancer Institute Grant CA-46535.

² To whom requests for reprints should be addressed.

Received 10/23/90. Accepted 1/22/91.

This article has been cited by other articles:

				A. Sharma, A. K. Sharma, S. V. Madhunapantula, D. Desai, S. J. Huh, P. Mosca, S. Amin, and G. P. Robertson Targeting Akt3 Signaling in Malignant Melanoma Using Isoselenocyanates Clin. Cancer Res., March 1, 2009; 15(5): 1674 - 1685. [Abstract] [Full Text] [PDF]

				E. Tseng, E. A. Scott-Ramsay, and M. E. Morris Dietary Organic Isothiocyanates Are Cytotoxic in Human Breast Cancer MCF-7 and Mammary Epithelial MCF-12A Cell Lines Experimental Biology and Medicine, September 1, 2004; 229(8): 835 - 842. [Abstract] [Full Text] [PDF]

				L. Tang and Y. Zhang Dietary Isothiocyanates Inhibit the Growth of Human Bladder Carcinoma Cells J. Nutr., August 1, 2004; 134(8): 2004 - 2010. [Abstract] [Full Text] [PDF]

				N. Miyoshi, S. Takabayashi, T. Osawa, and Y. Nakamura Benzyl isothiocyanate inhibits excessive superoxide generation in inflammatory leukocytes: implication for prevention against inflammation-related carcinogenesis Carcinogenesis, April 1, 2004; 25(4): 567 - 575. [Abstract] [Full Text] [PDF]

				V. W.Y. Lui, A. L. Wentzel, D. Xiao, K. L. Lew, S. V. Singh, and J. R. Grandis Requirement of a carbon spacer in benzyl isothiocyanate-mediated cytotoxicity and MAPK activation in head and neck squamous cell carcinoma Carcinogenesis, October 1, 2003; 24(10): 1705 - 1712. [Abstract] [Full Text] [PDF]

				K. Akagi, M. Sano, K. Ogawa, M. Hirose, H. Goshima, and T. Shirai Involvement of Toxicity as an Early Event in Urinary Bladder Carcinogenesis Induced by Phenethyl Isothiocyanate, Benzyl Isothiocyanate, and Analogues in F344 Rats Toxicol Pathol, June 1, 2003; 31(4): 388 - 396. [Abstract] [PDF]

				K. R.K. Sticha, P. M.J. Kenney, G. Boysen, H. Liang, X. Su, M. Wang, P. Upadhyaya, and S. S. Hecht Effects of benzyl isothiocyanate and phenethyl isothiocyanate on DNA adduct formation by a mixture of benzo[a]pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung Carcinogenesis, September 1, 2002; 23(9): 1433 - 1439. [Abstract] [Full Text] [PDF]

				A. Gupta, R. Nines, K. A. Rodrigo, R. A. Aziz, P. S. Carlton, D. L. Gray, V. E. Steele, M. A. Morse, and G. D. Stoner Effects of Dietary N-(4-Hydroxyphenyl)retinamide on N-Nitrosomethylbenzylamine Metabolism and Esophageal Tumorigenesis in the Fischer 344 Rat J Natl Cancer Inst, July 4, 2001; 93(13): 990 - 998. [Abstract] [Full Text] [PDF]

				S. S. Hecht Chemoprevention of Cancer by Isothiocyanates, Modifiers of Carcinogen Metabolism J. Nutr., March 1, 1999; 129(3): 768 - 768. [Abstract] [Full Text]

				C. C. Conaway, D. Jiao, T. Kohri, L. Liebes, and F.-L. Chung Disposition and Pharmacokinetics of Phenethyl Isothiocyanate and 6-Phenylhexyl Isothiocyanate in F344 Rats Drug Metab. Dispos., January 1, 1999; 27(1): 13 - 20. [Abstract] [Full Text]